BR9713489A - ácidos aminoalcanofosfÈnicos substituìdos - Google Patents

ácidos aminoalcanofosfÈnicos substituìdos

Info

Publication number
BR9713489A
BR9713489A BR9713489-9A BR9713489A BR9713489A BR 9713489 A BR9713489 A BR 9713489A BR 9713489 A BR9713489 A BR 9713489A BR 9713489 A BR9713489 A BR 9713489A
Authority
BR
Brazil
Prior art keywords
aliphatic
araliphatic
substituted
cycloaliphatic
acids
Prior art date
Application number
BR9713489-9A
Other languages
English (en)
Inventor
Pierre Acklin
Hans Allgeier
Yves Auberson
Silvio Ofner
Siem Jacob Veenstra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9713489A publication Critical patent/BR9713489A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção:<B>"áCIDOS AMINOALCANOFOSFÈNICOS SUBSTITUìDOS"<D>. Compostos da fórmula I na qual R~ 1~ representa hidróxi ou um radical alifático, aralifático ou aromático, X representa um radical alifático, cicloalifático, cicloalifático-alifático, aralifático, heteroarilalifático ou aromático bivalente, R~ 2~ representa hidrogênio ou um radical alifático ou aralifático, alk representa alquilideno inferior e R~ 3~, R~ 4~ e R~ 5~ independentes um do outro, representam hidrogênio, alquila inferior, halogênio, trifluormetila, ciano ou nitro e seus sais podem ser aplicados para o tratamento de estados patológicos, que respondem ao bloqueio de receptores de aminoácidos excitatórios e para a preparação de preparados farmacêuticos.
BR9713489-9A 1996-10-24 1997-10-22 ácidos aminoalcanofosfÈnicos substituìdos BR9713489A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH262196 1996-10-24
PCT/EP1997/005843 WO1998017672A1 (de) 1996-10-24 1997-10-22 Substituierte aminoalkanphosphonsäuren

Publications (1)

Publication Number Publication Date
BR9713489A true BR9713489A (pt) 2000-02-29

Family

ID=4237878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713489-9A BR9713489A (pt) 1996-10-24 1997-10-22 ácidos aminoalcanofosfÈnicos substituìdos

Country Status (23)

Country Link
US (1) US6117873A (pt)
EP (1) EP0934326B1 (pt)
JP (1) JP3908790B2 (pt)
KR (1) KR20000052747A (pt)
CN (1) CN1092202C (pt)
AT (1) ATE325128T1 (pt)
AU (1) AU5188598A (pt)
BR (1) BR9713489A (pt)
CA (1) CA2269807C (pt)
CZ (1) CZ141399A3 (pt)
DE (1) DE59712642D1 (pt)
ES (1) ES2264171T3 (pt)
HU (1) HUP0000383A3 (pt)
ID (1) ID21927A (pt)
IL (1) IL129394A (pt)
NO (1) NO991902L (pt)
NZ (1) NZ334891A (pt)
PL (1) PL192286B1 (pt)
PT (1) PT934326E (pt)
RU (1) RU2181362C2 (pt)
SK (1) SK282548B6 (pt)
TR (1) TR199900897T2 (pt)
WO (1) WO1998017672A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2645199A (en) * 1998-11-18 2000-06-05 Viktor Veniaminovich Tets Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methy lphosphonates
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AU2001294792B2 (en) * 2000-09-27 2006-12-14 Ilex Products, Inc. Alpha-substituted beta-aminoethyl phosphonates
US20030114421A1 (en) * 2000-09-27 2003-06-19 Phan Hieu Trung Alpha-substituted beta-aminoethyl phosphonate derivatives
GB0025849D0 (en) * 2000-10-23 2000-12-06 Smithkline Beecham Plc Novel compounds
US6492517B1 (en) 2001-07-19 2002-12-10 Air Products And Chemicals, Inc. Method for preparing halomethyl heterocyclic compounds
TW200403066A (en) * 2002-04-30 2004-03-01 Novartis Ag New uses of substituted aminoalkanephosphonic acids
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
GB0310868D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
GB0324541D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0324542D0 (en) * 2003-10-21 2003-11-26 Novartis Ag Organic compounds
GB0325172D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325173D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
GB0325390D0 (en) * 2003-10-30 2003-12-03 Novartis Ag Organic compounds
WO2005051298A2 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
WO2006107860A2 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
MX2007014501A (es) * 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos novedosos que contienen acido fosfinico.
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
GB0708507D0 (en) * 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
MX2010008922A (es) 2008-02-20 2010-09-07 Actelion Pharmaceuticals Ltd Compuestos antibioticos azatriciclicos.
AU2009276343A1 (en) 2008-08-01 2010-02-04 Bioxiness Pharmaceuticals, Inc. Methionine analogs and methods of using same
CN104151316B (zh) 2008-10-07 2016-06-15 埃科特莱茵药品有限公司 三环噁唑烷酮抗生素化合物
US8193372B2 (en) * 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
CN114409890A (zh) * 2022-02-28 2022-04-29 中国科学院长春应用化学研究所 一种氨基功能化的聚乙二醇衍生物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
US5118675A (en) * 1991-02-15 1992-06-02 American Home Products Corporation Quinoxaline phosphono-amino acids
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
SK2798A3 (en) * 1995-07-10 1998-07-08 Novartis Ag Novel quinoxaline- and quinoxalinylalkane-phosphonic acids
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives

Also Published As

Publication number Publication date
SK282548B6 (sk) 2002-10-08
NO991902D0 (no) 1999-04-21
ID21927A (id) 1999-08-12
EP0934326B1 (de) 2006-05-03
ES2264171T3 (es) 2006-12-16
AU5188598A (en) 1998-05-15
PL192286B1 (pl) 2006-09-29
WO1998017672A1 (de) 1998-04-30
DE59712642D1 (de) 2006-06-08
PL332775A1 (en) 1999-10-11
CA2269807C (en) 2007-04-10
TR199900897T2 (xx) 1999-07-21
KR20000052747A (ko) 2000-08-25
CZ141399A3 (cs) 1999-07-14
PT934326E (pt) 2006-08-31
IL129394A0 (en) 2000-02-17
IL129394A (en) 2002-05-23
NO991902L (no) 1999-06-21
CN1092202C (zh) 2002-10-09
HUP0000383A3 (en) 2003-01-28
JP2001502681A (ja) 2001-02-27
HUP0000383A2 (hu) 2001-05-28
RU2181362C2 (ru) 2002-04-20
ATE325128T1 (de) 2006-06-15
CN1234037A (zh) 1999-11-03
SK52399A3 (en) 2000-04-10
EP0934326A1 (de) 1999-08-11
NZ334891A (en) 2001-04-27
CA2269807A1 (en) 1998-04-30
JP3908790B2 (ja) 2007-04-25
US6117873A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
BR9713489A (pt) ácidos aminoalcanofosfÈnicos substituìdos
BR9712321A (pt) Aminotiofenocarboxamidas
BR0014078A (pt) Inibidores de fator xa
BR9812030A (pt) Combinações terapêuticas compreendendo amlodipina e atorvastatina
DE69532760D1 (de) Mittel zur verabreichung von antigenen
BG103552A (en) Therapeutical forms
BR9910032A (pt) Tienopirimidinas
FI972744A0 (fi) Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa
PT773022E (pt) Preparacao farmaceutica para o tratamento de rinites agudas contendo simpaticomimeticos e pantotenol e/ou acido pantotenico
BR9910329A (pt) Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto
BR0011778A (pt) Tienopirimidinas
BR9907025A (pt) Polissacarìdeos sintéticos, processo para sua preparação e composições farmacêuticas que contêm os mesmos
NO983864L (no) Morfin- og diamorfinsalter av anioniske, ikke-narkotiske analgetika av den substituerte karboksyltypen
TR199701121T1 (xx) Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
BR9611642A (pt) Compostos composição farmacéutica e processo para a preparação de compostos
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
BR9808424A (pt) Composto, processos para a preparação do mesmo, para a preparação dos intermediários e para tratamento de um mamìfero, incluindo o ser humano, composição farmacêutica, e, uso de um composto.
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida
DK0397646T3 (da) Farmaceutisk præparat til behandling af leversygdomme
BR9805246A (pt) Derivados de benzotiofeno úteis em terapia.
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
BR9713087A (pt) Composição farmacêutica estabilizada, utilização e processo para preparar a mesma, e, utilização de ácido metanossulfÈnico ou ácido clorìdrico
BR9813819A (pt) Derivados de p-aminofenol e seu emprego
BR0008479A (pt) Agonistas de 5-ht 1f
BR0207762A (pt) Uso de um composto ou um sal farmaceuticamente aceitável do mesmo, combinação, formulação farmacêutica, kit, método para a prevenção da úlcera gástrica induzida por medicamento, e, composição farmacêutica oral

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTIGOS 8O, 11 2O E 13 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: "ALTERADO DE INT.CL: C07F 9/6509

Ipc: C07F 9/6509 (2008.01), A61K 31/675 (2008.01), A61P

Free format text: ALTERADO DE INT.CL: C07F 9/6509; A61K 31/675; A61P 25/28

Ipc: C07F 9/6509 (2008.01), A61K 31/675 (2008.01), A61P

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229-C DA LPI.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]